Entrectinib (RXDX‐101) is another inhibitor of TrkA/B/C, and has been found to inhibit NB tumor growth, while entrectinib also augments the tumor growth inhibition of temozolomide when used in combination therapy in a xenograft mouse model.144. This evidence concerns the gene NTRK1 and neoplasm.